Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • jca
    Junior Member
    • Feb 2008
    • 2

    #1

    High duplicate rates in exomes

    Hello all,

    We are currently carrying out analysis of a series of exomes prepared using the Illumina TruSeq exome selection kit, which targets 62 Mb of the genome. The exomes range between 35 and 75 million 100 bp read pairs, giving us coverages in the order of 50-150x.

    Following alignment with BWA (with a mapping rate typically ~95-97%), local indel realignment with GATK and marking duplicates with picard, we are seeing extremely high rates of PCR duplicates (between 25-90%, but most commonly in the order of 40-60%). Obviously this means we are losing a huge amount of data if we persist with removing these duplicates.

    The arguments about wheter to mark duplicates or not have obviously been done to death here, but since these are the first exomes we've handled, I'm trying to understand if these results are 'normal' in exome sequencing. Clearly there is a much greater chance of identical reads occurring given the comparatively small target region, but is it normal to see such high rates of duplicate reads, or does this look more likely to to be a wet-lab issue (overamplificaion?).

    Thanks in advance for any advice anyone can give,
    James
  • Heisman
    Senior Member
    • Dec 2010
    • 534

    #2
    While a bit high, that is not necessarily crippling, even at 60%. I would remove them as it intuitively does not make sense to keep them. That is higher than expected, and it is probably caused by some/all of the following factors (although, to be fair, I have not done TruSeq exomes so perhaps this is more the norm with them):

    1. Having a small amount of input DNA into the entire prep.
    2. Having library prep reactions not perform optimally, thus causing a smaller percentage of your fragments to be amplified during the PCR.
    3. Too many PCR cycles for one reason or another (likely due to 1 or 2).

    Comment

    • ECO
      --Site Admin--
      • Oct 2007
      • 1360

      #3
      Anecdote of questionable value below...

      Just got my first data back from TruSeq Custom Enrichment using their cancer trial kit. It's only one capture containing 6 samples, but I'm seeing ~30% dups across the board for all 6. There was NO precapture PCR performed, only 10 cycles of post capture amp...this seems pretty high.

      We typically see <10% PCR dups from SureSelect panels of the same size, even though we do a small number of cycles pre-cap, and 10 after.

      I'm going to be on the hunt for more data points for performance/dups for TSCE. The fact that they perform two _identical_ sequential hybridizations (same probes, same temps, same washing conditions) says to me that they didn't develop the kit very well...so I'm skeptical of the performance of the protocol from this standpoint.

      Comment

      • kmcarr
        Senior Member
        • May 2008
        • 1181

        #4
        James,

        What % of the target regions are covered by reads? How even is that coverage (with and without duplicate removal)?

        Comment

        • jca
          Junior Member
          • Feb 2008
          • 2

          #5
          All,

          Thanks for all the comments. I've been looking further into this data, and have now obtained statistics for all our samples and can see there is a clear per-lane bias in the proportion of duplicates being found. While the per-lane average duplicate rate varies between 20% and 87%, the standard deviation on these figures is <5%, so there appears to be a distinct batch effect present. Without knowing how the samples were grouped for preparation it is hard to jump to any conclusions, but this looks extremely suspicious to me...

          Originally posted by kmcarr View Post
          What % of the target regions are covered by reads? How even is that coverage (with and without duplicate removal)?
          I'm in the process of generating those stats, and will update when I have them all available.

          Many thanks,
          James

          Comment

          Latest Articles

          Collapse

          • SEQadmin2
            Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
            by SEQadmin2


            Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

            The systematic characterization of the human proteome has
            ...
            07-20-2026, 11:48 AM
          • SEQadmin2
            Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
            by SEQadmin2



            Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
            ...
            07-09-2026, 11:10 AM
          • SEQadmin2
            Cancer Drug Resistance: The Lingering Barrier to Rising Survival
            by SEQadmin2



            Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

            There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
            07-08-2026, 05:17 AM

          ad_right_rmr

          Collapse

          News

          Collapse

          Topics Statistics Last Post
          Started by SEQadmin2, Today, 02:55 AM
          0 responses
          5 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 07-24-2026, 12:17 PM
          0 responses
          11 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 07-23-2026, 11:41 AM
          0 responses
          12 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 07-20-2026, 11:10 AM
          0 responses
          24 views
          0 reactions
          Last Post SEQadmin2  
          Working...